The year 2012 has been a great one for approvals for PharmaLogic. Four products on which we made substantial contributions were approved in the U.S. : iStent® Trabecular Micro-Bypass Stent, Jetrea® (ocriplasmin), Kyprolis® (carfilzomib), and Myrbetriq® (mirabegron).
- Value of medical writers discussed in top journal
- Client publishes 100th paper – PharmaLogic wrote the first one
- Dr. Novack’s paper among top 100 glaucoma papers
- Unintended consequences of off-label use
- Off-label use: Article in the American Journal of Ophthalmology
- PharmaLogic work contributes to glaucoma therapeutics